GLP1R and type 2 diabetes mellitus: The cardiovascular outcome trial LEADER showed that the occurrence of major adverse cardiovascular events (defined as nonfatal myocardial infarction, nonfatal stroke, and death from CVD) in high-risk patients with T2D was reduced by treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide when compared to placebo added to standard of care [3].